[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsed-andor-refractory-multiple-myeloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsed-andor-refractory-multiple-myeloma":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100527860",false,"NCT06153251","A Study to Assess BMS-986453 in Participants With Relapsed and\u002For Refractory Multiple Myeloma","A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and\u002For Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Participants must have a diagnosis of multiple myeloma with relapsed and\u002For refractory disease.\n* Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry.\n* Participants in Part A and Part B Cohort 1 and in Part B Cohort 2 must have relapsed\u002Frefractory multiple myeloma and received previous antimyeloma therapy, including a proteasome inhibitor and an immunomodulatory agent.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have adequate organ function.\n\nExclusion Criteria:\n\n* Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma.\n* Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis.\n* Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis.\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.","ALL","18 Years",{"count":18,"type":19},187,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The purpose of this study is to assess BMS-986453 in participants with relapsed and\u002For refractory multiple myeloma (RRMM).",[25],"Relapsed and\u002For Refractory Multiple Myeloma",[27,28,29,30,31,32,33,34],"Dual Targeting","BCMAxGPRC5D","GPRC5DxBCMA","BMS-986453","CAR T","CART","Multiple Myeloma","Relapsed and\u002For Refractory","RECRUITING","2026-03-16",{"date":38,"type":39},"2026-03-18","ACTUAL",{"date":41,"type":39},"2024-01-23",{"date":43,"type":19},"2030-05-02",{"name":45,"class":46},"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","INDUSTRY",19,{"id":49,"slug":4,"hasResults":10,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100530124","NCT06182696","OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R\u002FRMM","An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and\u002For Refractory Multiplemyeloma","Main Inclusion Criteria:\n\n* Diagnosis of R\u002FRMM according to the IMWG criteria;\n* Expected survival period is \\>12 weeks;\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2 at the time of ICF signature;\n* The expression of GPRC5D in bone marrow plasma cells membrane is more than 20% by flow cytometry and\u002For immunohistochemistry, multiple myeloma with measurable lesions, and at least one of the following criteria must be met:\n\n  1. Serum M protein \\>5 g\u002FL;\n  2. Urine M protein level \\>200 mg\u002F24 hour;\n  3. Serum free light chain (sFLC) \\>100 mg\u002FL and K\u002Fλ FLC ratio is abnormal;\n  4. Primitive immature or monoclonal plasma cells \\>5% by bone marrow cytology or flow cytometry.\n* Subjects who had received at least 3 prior lines of therapy including (but not limited to) immunomodulatory drugs (IMiDs), proteasome inhibitors, anti-CD38 monoclonal antibodies, etc., but have failed treatment, including those who have experienced relapse (within 12 months), refractory or intolerant to the last line treatment regimen.\n\nMain Exclusion Criteria:\n\n* Smoldering myeloma (asymptomatic)\n* Multiple myeloma with only extramedullary lesions;\n* Plasma cell leukemia;\n* Concurrent amyloidosis;\n* Central nervous system metastasis, leptomeningeal disease or metastatic central compression;\n* HBsAg or HbcAb is positive, and the quantitative detection of hepatitis B virus (HBV) DNA in peripheral blood is more than 100 copies\u002FL; hepatitis C virus (HCV) antibody and HCV RNA in peripheral blood is positive; human immunodeficiency virus (HIV) antibody positive; syphilis antibody is positive at Screening; Cytomegalovirus DNA test is positive;\n* Had hypersensitivity or intolerance to any drug\u002Fexcipient (including conditioning chemotherapy) used in this study;\n* Previously received treatment targeting GPRC5D, including but not limited to antibodies, ADC, or CAR-T;\n* Subjects who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks of Screening Visit or who plan to undergo ASCT during the study;\n* Any uncontrolled active infection within 4 weeks prior to ICF signing or leukapheresis requires parenteral antibiotic, antiviral, or antifungal treatment\n* Major surgery within 28 days prior to Screening Visit with the exception of a biopsy and an insertion of a central venous catheter or during the study;\n* Subjects who received allogeneic stem cell therapy;\n* Subjects complications or other conditions evaluated by investigators may affect compliance with the protocol or make them unsuitable to participate in this study;\n* Pregnant or breastfeeding.","75 Years",{"count":56,"type":19},83,[22,58],"PHASE2","An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R\u002FRMM",[25],"2024-05-30",{"date":63,"type":39},"2024-05-31",{"date":65,"type":39},"2023-10-26",{"date":67,"type":19},"2028-08-31",{"name":69,"class":46},"OriCell Therapeutics Co., Ltd.",5,""]